Coherus Biosciences reported $12.75M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
AbbVie USD 17.4B 410M Sep/2026
Acadia Pharmaceuticals USD 342M 34.04M Sep/2026
Akebia Therapeutics USD 57.62M 1.14M Dec/2025
ALKERMES USD 480.13M 15.88M Sep/2026
Alnylam Pharmaceuticals USD 1.46B 170M Sep/2026
Amarin USD 49.22M 451K Dec/2025
Amgen USD 10.4B 300M Sep/2026
Baxter International USD 2.98B 20M Sep/2026
Biogen USD 2.8B 60M Sep/2026
BioMarin Pharmaceutical USD 1.03B 40M Sep/2026
Bristol-Myers Squibb USD 13.07B 100M Sep/2026
Coherus Biosciences USD 12.75M 1.18M Dec/2025
Eli Lilly USD 24.4B 1.43B Sep/2026
Fujifilm JPY 885.02B 58.53B Sep/2026
Gilead Sciences USD 8.3B 500M Sep/2026
Ironwood Pharmaceuticals USD 113.04M 6.53M Jun/2026
Merck USD 18.1B 1.5B Sep/2026
Myriad Genetics USD 190.7M 9.7M Jun/2026
Pacira USD 176.65M 15.75M Sep/2026
Perrigo USD 989M 31M Sep/2026
Pfizer USD 16.6B 1.57B Sep/2026
PTC Therapeutics USD 357.8M 3.2M Sep/2026
Regeneron Pharmaceuticals USD 5.12B 830M Sep/2026
Sarepta Therapeutics USD 381.4M 19.9M Sep/2026
Teva Pharmaceutical Industries USD 4.37B 8.3B Sep/2026
Vertex Pharmaceuticals USD 3.44B 110M Sep/2026
Xencor USD 116.52M 65.3M Sep/2026
Zoetis USD 2.4B 100M Sep/2026